Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) announced patent number 12,221,654 was issued on February 11, 2025, by the United ...

New Patent expands patent estate covering Adial’s unique molecular genetic approach to diagnosing and potentially treating ...

The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...

After trialing a "single patient Investigational New Drug" (IND) which allowed him access to BPM31510, Chase has been cancer-free for 17 years. This year marks the 18th anniversary of my ongoing ...

More than 10 million babies have been born through IVF, yet the process is still invasive and costly. Plus, why a venture ...

Launch of Hyde Park Discovery between UChicago, Deerfield Management to accelerate research into life-saving treatments ...

Novo Nordisk announced plans for a longer phase III trial testing its investigational obesity drug CagriSema, with regulatory ...

Results from a new study published in Clinical and Translational Immunology found that dual-target antibody therapy can enhance cancer-fighting T cells more effectively than current single-target ...

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

Ac-SSO110 has now received FDA orphan drug designation and investigational new drug application clearance for the treatment ...

Adial Pharmaceuticals (ADIL) announced patent number 12,221,654 was issued on February 11, 2025, by the United States Patent and Trademark ...